Treating Meibomian Gland Dysfunction

The meibomian glands produce meibum — the lipid-rich secretion that contributes to the outer part of the tear film. In healthy glands, meibum must:

• •be produced
• •move through the gland and duct
• •reach the lid margin
• •spread across the tear film during blinking

A problem can occur at several points in this process. For example, there may be:

• •duct obstruction
• •thick or altered secretion
• •poor gland expressibility
• •abnormal lid-margin anatomy
• •inflammation
• •inadequate blinking
• •structural gland loss

Treatment therefore depends partly on which of these abnormalities is actually present.

Meibomian Gland Dysfunction (MGD): what actually happens inside the glands — coming soon

Sometimes — but not always. Obstruction is an important form of MGD. If meibum cannot leave the gland normally, improving secretion and outflow can be a reasonable treatment target. This is the rationale behind treatments such as heat, gland expression and some forms of thermal treatment.

But reducing MGD to “blocked glands” is too simplistic. Some patients may have abnormal secretion without severe obstruction. Others may have inflammatory lid disease. Some may have substantial structural gland changes. And someone with significant gland dropout cannot simply have the missing gland tissue “unblocked.”

A recent review of MGD treatments makes this distinction particularly clearly: current therapies may improve the function of remaining glands, but they do not regenerate glands that have already been lost.

Meibum is a complex mixture of lipids whose physical properties change with temperature. In MGD, altered meibum can become more difficult to express. Heating the eyelids can make the secretion more fluid and facilitate its movement from the glands.

That is the basic rationale behind warm compresses, heated masks and several in-office thermal devices. Clinical studies show that appropriately delivered eyelid warming can improve tear quality symptoms and some measures of meibomian gland function.

But an important detail is often missed: “warm” is not automatically the same as therapeutically effective heating. Temperature, duration, heat retention and how consistently treatment is performed all matter.

Warm Compresses & Heat for MGD

Heat can make meibum easier to move. But if secretion remains obstructed, mechanical pressure may help evacuate material from the gland. This is the rationale behind meibomian gland expression.

Expression can also provide useful information. What comes out? Is the secretion clear? Cloudy? Thick? Toothpaste-like? Does very little emerge? How many glands are expressible?

But there is an important limitation: one expression session does not necessarily tell us everything about the long-term functional potential of a gland. A gland that produces little or nothing during one examination is not automatically proven to be permanently nonfunctional. Technique, pressure, location, prior heating and severity of obstruction can all influence what is observed.

Meibomian Gland Expression as Treatment

Meibomian Gland Expression & Meibum Quality: the diagnostic side

This is a much harder question. Removing obstructed material can improve outflow from functioning glands. But we should distinguish between restoring secretion from an obstructed gland and regenerating gland tissue that has been lost. Current MGD therapies have not been established as methods for regenerating absent meibomian glands.

That distinction becomes especially important when interpreting meibography. If a gland looks abnormal on an image, treatment may improve its function if viable glandular tissue remains. But we should not promise that treatment will simply “grow the glands back.”

Meibography: what gland images can and can't tell you

Blinking matters because producing meibum is only part of the system. The secretion also needs to reach and spread across the ocular surface. Complete blinking helps distribute the lipid layer and is involved in normal meibomian gland function.

So if someone repeatedly blinks incompletely — particularly during prolonged concentrated screen work — treating the glands while ignoring blinking may leave an important contributor untouched.

This does not mean that incomplete blinking causes every case of MGD. It means that gland treatment sometimes needs to consider the mechanics around the glands, not just the secretion inside them.

Why Blinking Matters

Screens and Blinking

MGD can coexist with:

• •blepharitis
• •ocular rosacea
• •Demodex
• •and other lid-margin abnormalities

If one of those conditions is contributing to inflammation or gland dysfunction, treating the gland secretion alone may not address the entire problem. For example, someone with clinically important Demodex infestation needs a different targeted strategy than someone whose main finding is inspissated meibum without Demodex.

This is exactly why identifying the driver matters.

Blepharitis and Dry Eye

Ocular Rosacea and Dry Eye

Demodex Blepharitis and Dry Eye

IPL — intense pulsed light — is now one of the commonly discussed in-office treatments for MGD. It was originally developed for dermatologic applications and was later adopted for ocular-surface disease. Clinical trials and systematic reviews suggest that IPL can improve meibomian gland function, tear-film measures and symptoms in selected patients with MGD.

But IPL is particularly interesting because its proposed action is not simply “heating the meibum.” Several mechanisms have been proposed, including effects involving:

• •inflammation
• •abnormal superficial blood vessels
• •meibomian gland function
• •and possibly other biological pathways

The exact mechanism remains incompletely established. That matters because IPL should not simply be thought of as an expensive warm compress.

We devote a separate article to exactly what IPL is supposed to do, what evidence supports it, who has actually been studied, and what its limitations and risks are.

IPL for Dry Eye and MGD

Thermal pulsation systems combine controlled eyelid heating with mechanical pressure intended to improve meibomian gland outflow. The principle is therefore relatively intuitive: heat the glands and facilitate evacuation.

Studies have found improvements in some symptoms and objective measures of MGD after thermal pulsation. An American Academy of Ophthalmology evidence review concluded that a single thermal pulsation session may safely improve subjective or objective parameters, while also noting that some independent studies found outcomes not significantly different from conventional warm compresses or lid hygiene. More recent evidence remains mixed depending on the outcome measured.

So thermal pulsation is a legitimate MGD treatment option. But more technologically sophisticated does not automatically mean better for every patient.

Thermal Pulsation for MGD

We cannot currently answer that confidently. A 2025 systematic review examined randomized trials of IPL and LipiFlow, but importantly none of the included trials directly compared IPL with LipiFlow. The apparent differences therefore came from indirect comparisons across different studies with different control groups. The authors specifically cautioned against drawing strong conclusions about which treatment is superior.

This is a very useful example of something we will repeatedly encounter in dry-eye treatment research: “Both treatments have evidence” does not mean we know which one is better.

Radiofrequency — RF — has also entered the MGD treatment landscape. It uses controlled energy to heat tissue and is proposed to improve meibomian gland function and secretion.

But as with every newer device-based treatment, we need to separate the proposed mechanism from what high-quality clinical evidence has actually demonstrated. We therefore look at RF separately rather than grouping all forms of “heating” together.

Radiofrequency (RF) for MGD and Dry Eye

No. TFOS DEWS III describes warm compresses as a typical treatment for MGD while also reviewing numerous in-office options, including device-based eyelid heating and IPL.

For some people, relatively simple home management may be sufficient. For others, home treatment may be impractical, inadequately effective or poorly tolerated. And some forms or severities of MGD may lead clinicians to consider in-office therapy. The existence of a more advanced procedure does not automatically mean everyone with MGD needs it.

Not every treatment for MGD has to act directly on the glands. If poor meibomian secretion results in an inadequate tear-film lipid layer, lipid-containing lubricants may temporarily support the tear film.

But there is an important distinction: supporting the lipid layer is not necessarily the same thing as restoring meibomian gland function. Both may be useful. They simply have different targets.

Artificial Tears & Dry Eye Drops: lubricating drops in the ocular-surface protection section

This is one of the questions patients understandably care about most. If meibography shows gland loss, the natural fear is: “Will I keep losing glands?”

MGD is considered a chronic disorder, and structural changes can occur. But predicting progression in an individual patient is difficult. Current treatments are generally intended to improve gland function, secretion, tear-film stability and symptoms. We do not have strong evidence that allows us to promise that a particular treatment will permanently stop structural progression in every patient.

And we should be especially cautious about claims that a treatment regenerates lost glands. Current evidence does not support that as an established outcome of routine MGD therapy.

No. Meibography is important, but it is not the same thing as a complete functional assessment. A person can have structural gland loss while remaining glands still produce secretion. Conversely, glands that look relatively preserved on imaging may function poorly.

So treatment decisions should not be based on the dropout percentage alone. The practical question is: what viable gland function remains, what is abnormal about it, and can that function be improved?

It is more useful to think about management and function than to promise a universal cure. MGD is generally considered a chronic disorder. But chronic does not mean that nothing can improve. Gland secretion can improve. Obstruction can improve. Tear-film stability can improve. Symptoms can improve substantially. And treatment needs can change over time.

The goal is not necessarily to produce a perfect meibography image. The goal is to create a tear-film system that functions well enough to protect the ocular surface and allow the person to live comfortably.

This is where we return to the framework from the previous article. Before treatment, define the target. Then reassess it. Depending on the problem, useful outcomes may include:

• •meibum becoming easier to express
• •improved secretion quality
• •more functioning glands yielding secretion
• •better tear-film stability
• •improved lipid-layer behavior
• •less ocular-surface staining
• •fewer symptoms
• •better real-life function

Not every measurement needs to improve. And symptoms may not change at exactly the same rate as gland findings.

Then we should not automatically keep escalating MGD treatment. Perhaps another driver remains. There may also be:

• •aqueous deficiency
• •ocular-surface inflammation
• •exposure
• •abnormal blinking
• •allergy
• •a neural component to persistent symptoms

This is one of the dangers of receiving an MGD diagnosis: everything that happens afterward can start being attributed to the glands. But MGD can improve while another component of dry eye remains.

Dry Eye Is Often Mixed

Aqueous Deficiency

Neural Dysfunction

That can happen too. Treatment goals are not necessarily anatomical perfection. If tear-film function improves sufficiently and the person becomes comfortable and functional, that is meaningful. Dry-eye treatment should not become an endless attempt to make every test result look normal.

There is no universal hierarchy that works for everyone. Useful questions include:

• •What form of MGD do I have?
• •Are the glands obstructed?
• •What is the meibum like?
• •How much functioning gland tissue remains?
• •Is lid-margin inflammation present?
• •Is rosacea or Demodex involved?
• •Is blinking contributing?
• •What exactly is the proposed treatment supposed to change?
• •How strong is the evidence for that treatment in patients like me?
• •What are the risks, costs and practical burden?

And finally: how will we know whether it worked?

That is much more useful than asking “Which MGD treatment is the strongest?”